secwatch / observer
8-K filed October 6, 2023, 7:59 PM ET ticker ZNTL CIK 0001725160
leadership confidence high sentiment neutral materiality 0.50

Zentalis Pharmaceuticals COO Iris Roth departs effective Oct 10, 2023

Zentalis Pharmaceuticals, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Iris Roth

Chief Operating Officer
ZNTL · Zentalis Pharmaceuticals, Inc.
Effective
2023-10-10
Filed
October 6, 2023, 7:59 PM ET
On Friday, October 6, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced that Iris Roth, Ph.D., Chief Operating Officer of the Company, will depart from the Company and cease serving as Chief Operating Officer of the Company, effective as of 11:59 p.m. Eastern Time on Tuesday, October 10, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Iris Roth departed as Chief Operating Officer at Zentalis Pharmaceuticals, Inc..

Action
depart
Role
Chief Operating Officer
Exact text from the filing
On Friday, October 6, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced that Iris Roth, Ph.D., Chief Operating Officer of the Company, will depart from the Company and cease serving as Chief Operating Officer of the Company, effective as of 11:59 p.m. Eastern Time on Tuesday, October 10, 2023.
View on SEC.gov

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0001725160-23-000178
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.